Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29100398 | 0.96 | TLR8 (0.40) | CNR1TLR8ALOX15CNR2DHFR | |
| SCHEMBL15658141 | 0.89 | GAA (0.41) | TLR8MEN1ALDH1A1RAB9AKMT2A | |
| SCHEMBL3265241 | 0.84 | TLR8 (0.40) | CNR1TLR8CNR2MEN1ALDH1A1 | |
| SCHEMBL15660484 | 0.83 | GAA (0.41) | CNR1TLR8CNR2MEN1ALDH1A1 | |
| SCHEMBL15657877 | 0.83 | GAA (0.41) | CNR1TLR8CNR2MEN1ALDH1A1 | |
| SCHEMBL15659112 | 0.83 | GAA (0.41) | CNR1TLR8CNR2MEN1ALDH1A1 | |
| SCHEMBL15657108 | 0.79 | MAPT (0.40) | TLR8DNMT1ALDH1A1MAPTGAA | |
| SCHEMBL8662481 | 0.79 | HTR1B (0.40) | CNR1TLR8CNR2MEN1ALDH1A1 | |
| SCHEMBL15657586 | 0.78 | GAA (0.40) | CNR1TLR8MEN1ALDH1A1RAB9A | |
| SCHEMBL1933967 | 0.78 | DNMT1 (0.39) | DHFRDNMT1MEN1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2506713-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-1989194-B1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | RUEEGER HEINRICH | 2009-04-16 | — | — | US | disclosed |
| EP-1989194-A1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007093621-A1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | CNR1 709/4885TLR8 4384/4885ALOX15 2677/4885 |
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | BACE1, BACE2, APP | CNR1 1827/4885TLR8 4703/4885ALOX15 2049/4885 |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | CNR1 219/4885TLR8 1001/4885ALOX15 597/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | CNR1 219/4885TLR8 1001/4885ALOX15 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.